Practical insights into medications and therapies. Mechanisms of action, dosing, side effects, interactions, and treatment monitoring. No oversimplifications from leaflets—based on up-to-date literature and clinical guidelines.
Andropause, also referred to as late-onset hypogonadism, is often discussed with excessive caution, as if the very idea of treatment were questionable. In reality, for men with a confirmed deficiency, it’s a treatable condition, and androgen therapy is the established first-line option.
Read moreThe lab results show a number with the note "within normal range," yet you've been struggling with fatigue, low libido, and a drop in mood for months. Does that mean testosterone is definitely not the issue? Not necessarily. The word "normal" on a lab report doesn't always mean "everything's fine," and a single number without context can be misleading.
Read moreThere’s a lot of misunderstanding surrounding this term. The most common misconception is that off-label use is either illegal or experimental. Neither of these descriptions is accurate. Off-label simply means that a particular use of a drug hasn’t gone through the formal registration process for that specific indication. The drug itself is approved, available on the market, and comes with official documentation. It’s just being used in a way that differs from what’s outlined in the registration
Read moreDiscover how caffeine, theobromine, and L-theanine enhance focus, combat drowsiness, and elevate mood without the jittery side effects. Learn the mechanisms behind their action, optimal dosing, and the safety profile of combining 100 mg of caffeine with theobromine and L-theanine.
Read moreAffector is an editorial publication run by Codeenable, a software studio. We publish two parallel beats: one on pharmaceuticals, medicine, biology and life sciences; one on software, its architecture, AI and cloud. We chose this combination on purpose, not by accident.
Affector writes about pharmaceuticals, medicine, biology and the life and human sciences, and also about the technical underpinnings that make these fields advance.
We publish across domains that touch both the core subjects, pharma and medicine, and the technical craft that supports them - software, its architecture, and the current dominance of cloud solutions and AI.
Both silos genuinely interest our team, and the need to integrate digital techniques into medicine, pharma and the human sciences is growing at an avalanche pace.
Without cooperation with software teams, real progress in medicine and pharma is hard to come by today, and the most ambitious engineering projects increasingly emerge in response to real problems in biology and the clinic.
Hence the long-form, sourced writing that does not flinch at code or at clinical detail, producing a unique combination that is genuinely useful to clinicians and engineers alike.
